All In Biotech

Drug Trial Radar · NCT01747577

Post Marketing Study to Evaluate the Efficacy and Safety of Solifenacin in Patients With OAB (Overactive Bladder) After TURP (Trans-urethral Resection of Prostate) or PVP (Photoselective Vaporization of Prostate)

A Randomized, Double-blind, Placebo-controlled, Parallel-group, and Phase IV Study of Efficacy and Safety of Solifenacin Succinate in Patients With Overactive Bladder After TURP or PVP

Last checked: Nov 20, 2026Latest source record: Nov 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

68

Actual

Start

Dec 4, 2012

Primary completion

Oct 24, 2013

Study completion Oct 24, 2013

Sponsor

Lead sponsor
Astellas Pharma Korea, Inc.Astellas (ALPMY)
Sponsor type
Industry
First posted
Dec 11, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Male only, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to demonstrate superiority of the solifenacin succinate (treatment) over the placebo (control) based on the change from the baseline in the mean number of urgency episodes per 24 hours after 2 weeks.

Conditions

  • Overactive Bladder
  • Benign Prostate Hyperplasia
  • Transurethral Resection of Prostate
  • Photoselective Vaporization Prostatectomy

Interventions

  • Solifenacin SuccinateDrug

    Oral

  • PlaceboDrug

    Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean change from the baseline in the number of urgency episodes per 24 hrs in the voiding diary at Week 2Time frame: Baseline and at week 2

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.